Tris Pharma News and Activities

View the org chart displaying its 23 main executives

Most searched biographies at Tris Pharma

• Ketan Mehta, Chief Executive Officer and President
• Jim Potenziano, Chief Science and Development Officer
• Cheryl Patnick, Vice President, Human Resources

Popular executive movements at Tris Pharma

• Jim Potenziano, who was Vice President, Medical Affairs, is promoted to Chief Science and Development Officer  (posted on May 6 2026).

Create your alert
to follow the executive moves at Tris Pharma.

Tris Pharma has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott

Learn more about the Pharmaceuticals industry

Press releases by Tris Pharma

• Media Highlights and Coverage | Tris Pharma
• Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD | Tris Pharma
• Tris Pharma Appoints Michael Magee as Vice President, Quality & Compliance | Tris Pharma
• Tris Pharma Appoints Franchesca Fowler to Chief Compliance Officer and Vice President, General Counsel | Tris Pharma
• Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL® XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder | Tris Pharma
• Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder | Tris Pharma
• Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference | Tris Pharma
• Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH's National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder | Tris Pharma
• Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline | Tris Pharma
• Tris Pharma Announces FDA Approval of DYANAVEL® XR (amphetamine) Once-Daily Extended-Release Oral Tablets, CII, for ADHD | Tris Pharma
• View more press releases Close

Social media about Tris Pharma

• Tris Pharma on Wikipedia, Google News & Yahoo Finance
• Tris Pharma on LinkedIn, X (Twitter) & YouTube